



Erratum to development and validation of an individualized gene expression-based signature to predict overall survival in metastatic colorectal cancer

Editorial Office

Annals of Translational Medicine

Correspondence to: Editorial Office, Annals of Translational Medicine. Email: editor@atmjournals.org.

Submitted Jun 07, 2022. Accepted for publication Jun 18, 2022

doi: 10.21037/atm-2022-17

View this article at: <https://dx.doi.org/10.21037/atm-2022-17>

Erratum to: Ann Transl Med 2020;8:96

In the article (1) entitled “Development and validation of an individualized gene expression-based signature to predict overall survival in metastatic colorectal cancer” (Ann Transl Med 2020;8:96, doi: 10.21037/atm.2019.12.112), a mistake was made in the funding information. The funding sources of two grants (No. 2019B020229002, No. 201902020009) are incorrect. For correction, the funding source of No. 2019B020229002 should be Key-Area Research and Development Program of Guangdong Province, and the funding source of No. 201902020009 should be Science and Technology Planning Project of Guangzhou.

The correct Funding information is listed as below: Funding: This work was supported by National Natural Science Foundation of China (Grant Nos. 81703060, 81802441), Natural Science Foundation of Guangdong Province (Grant No. 2017A030310644), China Postdoctoral Science Foundation funded project (Grant No. 2018T110911), the National Key Research and Development Program of China (No. 2017YFC1308800), Science and Technology Planning Project of Guangdong Province (Nos. 20160916, 2014SC111), and National Key Clinical Discipline, Key-Area Research and Development Program of Guangdong Province (No. 2019B020229002), Science and Technology Planning Project of Guangzhou (No. 201902020009).

The authors confirmed this error did not affect either the results or the conclusions of the paper.

Click [here](#) to view the updated version of the article.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Ye SB, Cheng YK, Hu JC, et al. Development and validation of an individualized gene expression-based signature to predict overall survival in metastatic colorectal cancer. *Ann Transl Med* 2020;8:96.

Cite this article as: Editorial Office. Erratum to development and validation of an individualized gene expression-based signature to predict overall survival in metastatic colorectal cancer. *Ann Transl Med* 2022;10(15):846. doi: 10.21037/atm-2022-17